Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

NCT05980949 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

800

Enrollment

INDUSTRY

Sponsor class

Conditions

Psychosis Associated With Alzheimer's Disease

Interventions

DRUG: KarXT

Sponsor

Karuna Therapeutics, Inc., a Bristol Myers Squibb company